GLP-1 receptor agonists were tied to a 16% lower risk of epilepsy in adults with type 2 diabetes. Epilepsy is an ...

The study thus suggests yet another unexpected avenue for the GLP-1 drugs.

Two of the most closely watched Alzheimer clinical trials of the decade have delivered a sobering verdict: GLP-1 drugs that ...

A new review of nearly 100,000 participants suggests that glucagon-like peptide-1 receptor agonists (GLP-1RAs), popular ...

GLP-1 RAs probably have little or no effect on risk for thyroid cancer, pancreatic cancer, breast cancer, or kidney cancer.

With the skyrocketing popularity of GLP-1 RAs, some lesser-known side effects, including anemia, are coming to light.

The U.S. Food & Drug Administration (FDA) has approved certain GLP-1 drugs for commercialization and use, including liraglutide (Victoza®), semaglutide (Ozempic®, Wegovy®), and tirzepatide (Mounjaro®, ...

Psoriasis and psoriatic arthritis (PsA) are chronic, immune-mediated inflammatory diseases associated with several shared common comorbidities, of which obesity is one of the most prevalent. A complex ...

Migraines are one of the world's most common neurological conditions, impacting nearly 15% of people globally. Despite this widespread impact, many sufferers find current preventive treatments ...

Pharmaceutical vending machine at an airport. Image by Tim Sandle. Pharmaceutical vending machine at an airport. Image by Tim Sandle. Can a new discovery usher in a new generation of GLP-1 peptides – ...

A preliminary study of people with diabetes suggests that use of glucose-lowering GLP-1 drugs may be linked to a lower risk ...

A large US database study suggests GLP-1 receptor agonists may be associated with a reduced risk of developing epilepsy in ...